Stay informed on the latest developments, milestones, and announcements from Vector Science & Therapeutics.
Vector Science & Therapeutics Corp. (TSXV: PAIN) today announced the appointment of Darryl Drake Jr. as President of Valor and Chairman of the Valor Advisory Board, strengthening the Company’s leadership team as it advances its precision therapeutics platform.
Vector Science & Therapeutics Corp. (TSXV: PAIN) has entered into an option agreement to acquire up to a 15% equity interest in LyoGenesis Plus for up to US$1,000,000, securing pharmaceutical-grade cGMP manufacturing access through an FDA-registered, 35,000 sq. ft. facility in Mequon, Wisconsin, to support its growing portfolio of 22 novel peptide formulations.
Vector Science & Therapeutics Corp. (TSXV: PAIN) announces it has entered into a three-year development and manufacturing agreement with MPP Group LLC, a key milestone advancing the Company’s therapeutic delivery platform toward commercial-scale production.
Vector Science & Therapeutics Corp. (TSXV: PAIN) announces the filing of a provisional patent application covering a novel microneedle catheter platform designed to enable precise, minimally invasive intratumoral drug delivery, advancing the Company’s site-directed therapeutic intervention portfolio.
Vector Science and Therapeutics Corp. (TSXV: PAIN) appoints The Honourable Tommy G. Thompson, former U.S. Secretary of Health and Human Services and 42nd Governor of Wisconsin, as Chairman of the Board of Directors, bringing decades of health policy and government leadership experience.
Vector Science and Therapeutics Corp. (TSXV: PAIN) announces the completion of its qualifying transaction and listing on the TSX Venture Exchange, marking a significant milestone with access to Canadian public capital markets to advance its biomechanical and transdermal drug delivery platforms.
Vector Science & Therapeutics Inc. has entered into a definitive agreement for a reverse merger with OpenSesame Acquisition Corp., a significant step toward listing on the TSX Venture Exchange (TSXV), providing access to Canadian public capital markets.
For media inquiries, investor relations, or press kit requests, please contact our team directly.
info@vectorscience.co